All News

"The next-generation Optilume BPH Catheter System offers a safe and effective new, minimally invasive treatment for BPH, reducing urinary obstruction with a low rate of sexual or other adverse effects," says Steven A. Kaplan, MD.

Data among patients with follow-up of greater than 48 months demonstrated an IPSS reduction of 45.2% from baseline to 79 months following treatment.

The minimally invasive surgical therapy Optilume was recently approved by the FDA for the treatment of lower urinary tract symptoms secondary to BPH.

Data showed a decrease in patient symptoms following Aquablation procedures, with an average IPSS of 22.6 at baseline compared with 6.8 at 5-year follow-up.

The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH.

"One of the things that made a difference, at least in my practice, was one of the newer pulse modulated holmium lasers," says Smita De, MD, PhD.

The data were presented at the recent American Urological Association Annual Meeting.

Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).